JP2024521897A5 - - Google Patents

Info

Publication number
JP2024521897A5
JP2024521897A5 JP2023574349A JP2023574349A JP2024521897A5 JP 2024521897 A5 JP2024521897 A5 JP 2024521897A5 JP 2023574349 A JP2023574349 A JP 2023574349A JP 2023574349 A JP2023574349 A JP 2023574349A JP 2024521897 A5 JP2024521897 A5 JP 2024521897A5
Authority
JP
Japan
Application number
JP2023574349A
Other languages
Japanese (ja)
Other versions
JPWO2022256565A5 (https=
JP2024521897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/032014 external-priority patent/WO2022256565A2/en
Publication of JP2024521897A publication Critical patent/JP2024521897A/ja
Publication of JP2024521897A5 publication Critical patent/JP2024521897A5/ja
Publication of JPWO2022256565A5 publication Critical patent/JPWO2022256565A5/ja
Pending legal-status Critical Current

Links

JP2023574349A 2021-06-02 2022-06-02 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法 Pending JP2024521897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195993P 2021-06-02 2021-06-02
US63/195,993 2021-06-02
PCT/US2022/032014 WO2022256565A2 (en) 2021-06-02 2022-06-02 Compositions and methods for delivering therapeutic oligonucleotides to the central nervous system

Publications (3)

Publication Number Publication Date
JP2024521897A JP2024521897A (ja) 2024-06-04
JP2024521897A5 true JP2024521897A5 (https=) 2025-05-28
JPWO2022256565A5 JPWO2022256565A5 (https=) 2025-05-28

Family

ID=84324589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574349A Pending JP2024521897A (ja) 2021-06-02 2022-06-02 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法

Country Status (9)

Country Link
US (1) US20240287526A1 (https=)
EP (1) EP4346845A2 (https=)
JP (1) JP2024521897A (https=)
KR (1) KR20240038930A (https=)
CN (1) CN117795069A (https=)
AU (1) AU2022286420A1 (https=)
CA (1) CA3222212A1 (https=)
IL (1) IL308994A (https=)
WO (1) WO2022256565A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319764A (en) * 2022-09-28 2025-05-01 Atalanta Therapeutics Inc Compositions and methods for treating Huntington's disease
WO2024169770A1 (zh) * 2023-02-17 2024-08-22 苏州时安生物技术有限公司 一种抑制SCN9A基因表达的siRNA、其药物组合物及用途
JP2026509929A (ja) * 2023-03-23 2026-03-25 アタランタ セラピューティクス,インコーポレーテッド 改善された遺伝子サイレンシングのための組成物及び方法
WO2025111497A1 (en) * 2023-11-21 2025-05-30 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating acute activation
WO2025193786A1 (en) * 2024-03-12 2025-09-18 University Of Massachusetts Oligonucleotides for prnp modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125147A1 (en) * 2014-02-20 2015-08-27 B. G. Negev Technologies And Applications Ltd Anionic polyplexes for use in the delivery of nucleic acids
WO2019122279A1 (en) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage

Similar Documents

Publication Publication Date Title
JP2024521897A5 (https=)
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13145U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13166U (https=)
BY13143U (https=)
BY13144U (https=)
BY13168U (https=)
BY13149U (https=)